Related Experiment Videos
Collagen crosslinked N-telopeptides as markers for evaluating particulate osteolysis: a preliminary study
1Division of Orthopaedics, Royal Victoria Hospital, Montreal, Quebec, Canada. janton@orl.mcgill.ca
Summary
A urinary bone resorption marker, crosslinked N-telopeptide, can diagnose periprosthetic osteolysis and assess treatment effectiveness. Levels decreased after Fosamax treatment, indicating suppressed osteoclast activity.
Area of Science:
- Orthopedics
- Biochemistry
- Pharmacology
Background:
- Periprosthetic osteolysis is a complication of joint arthroplasty.
- Assessing and monitoring osteolysis noninvasively remains a clinical challenge.
- Osteoclast-mediated bone resorption is implicated in osteolysis progression.
Purpose of the Study:
- To evaluate crosslinked N-telopeptide as a noninvasive marker for diagnosing periprosthetic osteolysis.
- To assess the efficacy of Fosamax (alendronate) in treating osteolysis by measuring changes in N-telopeptide levels.
Main Methods:
- Collected second-morning urine from controls, hip arthroplasty patients without osteolysis, and patients with osteolysis.
- Quantified crosslinked N-telopeptides of type-I collagen using enzyme-linked immunosorbent assay.
- Monitored N-telopeptide levels before and after 6 weeks of daily 10-mg Fosamax treatment in osteolysis patients.
Main Results:
- Patients with osteolysis exhibited significantly elevated N-telopeptide levels compared to controls.
- N-telopeptide levels significantly decreased following Fosamax treatment.
- The study included young men and women to minimize menopausal bone resorption confounding factors.
Conclusions:
- Systemic bone resorption markers, like N-telopeptide, can effectively evaluate localized osteolysis and its treatment response.
- Osteolysis is associated with heightened osteoclast activity, which can be inhibited by bisphosphonates such as Fosamax.
- Findings support the use of N-telopeptide for understanding and managing aseptic loosening.